Hosted on MSN
Shut down the FDA’s failed GLP-1 green list
People taking GLP-1 drugs deserve to know exactly what is being injected into their bodies. A new Food and Drug Administration warning letter shows why they may not. The FDA warned Harbin Jixianglong ...
The FDA’s recent inclusion of certain GLP-1 receptor agonists on a so-called “Green List” is often portrayed as a regulatory milestone aimed at ensuring safer access to these increasingly popular ...
In recent years, the rise of glucagon-like peptide-1 (GLP-1) therapies has transformed the landscape of diabetes and obesity treatment. However, the FDA’s Green List has inadvertently created a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results